---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015768"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:08:21.533178+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 net loss $35.7M; cash $277.4M; PC14586 combo with KEYTRUDA planned

## Summary
- Net loss for H1 2022: $35.7M vs $24.5M YoY; cash, cash equivalents and marketable securities $277.4M as of June 30, 2022.
- R&D expenses $23.3M in H1 2022 vs $15.2M in H1 2021, driven by PC14586 clinical trial costs.
- Initial PC14586 Phase 1 data presented at ASCO; entered clinical collaboration with Merck for PC14586 + KEYTRUDA combo trial starting Q4 2022.
- Appointed Marc Fellous, M.D. as VP, Clinical Development and Medical Affairs; previous experience at Bayer and Roche.
- Net cash used in operations $31.7M in H1 2022 vs $22.1M in H1 2021; cash burn increased 43%.

## SEC filing metadata
- accession: 0000950170-22-015768
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/0000950170-22-015768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017022015768/pmvp-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015768
- JSON: https://secwatch.observer/filing/0000950170-22-015768.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.